Original Article
HER2 and Response to Paclitaxel in Node-Positive Breast Cancer
N Engl J Med 2007; 357:1496-1506October 11, 2007
- Abstract
Background
The status of human epidermal growth factor receptor type 2 (HER2) in breast-cancer cells predicts clinical outcomes in women who receive adjuvant anthracycline-based chemotherapy. We hypothesized that HER2 positivity predicts a benefit from adjuvant doxorubicin doses above standard levels, from the addition of paclitaxel after adjuvant chemotherapy with doxorubicin plus cyclophosphamide, or from both.
Methods
We randomly selected 1500 women from 3121 women with node-positive breast cancer who had been randomly assigned to receive doxorubicin (60, 75, or 90 mg per square meter of body-surface area) plus cyclophosphamide (600 mg per square meter) for four cycles, followed by four cycles of paclitaxel (175 mg per square meter) or observation. Tissue blocks from 1322 of these 1500 women were available. Immunohistochemical analyses of these tissue specimens for HER2 with the CB11 monoclonal antibody against HER2 or with a polyclonal-antibody assay kit and fluorescence in situ hybridization for HER2 amplification were performed.
Results
No interaction was observed between HER2 positivity and doxorubicin doses above 60 mg per square meter. HER2 positivity was, however, associated with a significant benefit from paclitaxel. The interaction between HER2 positivity and the addition of paclitaxel to the treatment was associated with a hazard ratio for recurrence of 0.59 (P=0.01). Patients with a HER2-positive breast cancer benefited from paclitaxel, regardless of estrogen-receptor status, but paclitaxel did not benefit patients with HER2-negative, estrogen-receptor–positive cancers.
Conclusions
The expression or amplification, or both, of HER2 by a breast cancer is associated with a benefit from the addition of paclitaxel after adjuvant treatment with doxorubicin (<60 mg per square meter) plus cyclophosphamide in node-positive breast cancer, regardless of estrogen-receptor status. Patients with HER2-negative, estrogen-receptor–positive, node-positive breast cancer may gain little benefit from the administration of paclitaxel after adjuvant chemotherapy with doxorubicin plus cyclophosphamide.
Media in This Article
Figure 1
Clinical Outcomes in Patients Treated with or without Paclitaxel, According to HER2 Status.Figure 2
Disease-free Survival among Patients Treated with or without Paclitaxel According to Estrogen-Receptor Status and HER2 Expression.Article Activity
- Article
Adjuvant chemotherapy improves disease-free and overall survival in early-stage breast cancer,1 and anthracyclines and taxanes are two of the most active agents in such treatment.2 The Cancer and Leukemia Group B (CALGB) 8541 trial showed that increasing the dose of a doxorubicin (Adriamycin)–based regimen from a relatively low dose (30 mg per square meter of body-surface area) to what is now considered to be a standard dose (60 mg per square meter) is highly beneficial.3,4 Subsequently, a randomized trial (CALGB 9344/INT0148) examined the effects of increased doses of doxorubicin, above 60 mg per square meter, when combined with cyclophosphamide (Cytoxan) at a dose of 600 mg per square meter, plus four subsequent cycles of paclitaxel (Taxol). Overall, there was no benefit from doses of doxorubicin above 60 mg per square meter, but the addition of paclitaxel improved both disease-free survival and overall survival.5
Adjuvant chemotherapy causes substantial morbidity and occasional life-threatening toxic effects, and it is costly. No biomarkers have been identified that can reliably predict a clinical benefit from paclitaxel or escalating doses of doxorubicin in women with breast cancer. HER2, a member of the epidermal growth factor receptor family, is amplified, overexpressed, or both in 15 to 20% of breast cancers.6 HER2 overexpression and amplification in breast-cancer cells are strong predictors of a benefit from treatment with trastuzumab,7 and the status of HER2 in the tumor might predict the results of other treatments of breast cancer.8 In a correlative study of breast-cancer tissues from trial 8541, HER2 amplification and overexpression were associated with benefits from standard doses of doxorubicin but not from low doses of doxorubicin.9-11 However, no studies have examined whether the overexpression or amplification of HER2 can predict a benefit of increasing the dose of doxorubicin above 60 mg per square meter. Results of preclinical studies and preliminary clinical studies regarding an interaction between HER2 status and paclitaxel are inconsistent.12-23 For these reasons, we investigated whether HER2 expression in the tumor identifies patients with breast cancer who are likely to benefit from doses of doxorubicin above 60 mg per square meter, the addition of paclitaxel after adjuvant treatment with doxorubicin plus cyclophosphamide, or both.
Methods
Patients
Patients eligible for CALGB 9344/INT0148 (enrollment period, May 1994 to April 1999) were women with node-positive breast cancer who had completed surgery with negative margins and were appropriate candidates for adjuvant chemotherapy.5 A total of 3121 patients were treated according to this protocol. All patients provided written informed consent.
Tissue Collection, Processing, Storage, and Distribution
Approximately 90% of women enrolled in this trial gave written informed consent for the collection, storage, and analysis of formalin-fixed paraffin-embedded primary breast-cancer tissue. A tissue block or unstained tissue sections were requested from each patient's primary institution by the pathology coordinating office of each of the participating cooperative groups (CALGB, Southwest Oncology Group, Eastern Cooperative Oncology Group, and North Central Cancer Treatment Group) and were collected at the CALGB pathology coordinating office. Coded tissue sections were placed on glass slides without any patient identifiers and were distributed to the various investigators' laboratories for analysis in a blinded fashion. HER2 data were submitted by each investigator to the CALGB Statistical Center for correlations with clinical outcomes.
Estrogen-receptor status was determined by the local institutions by means of standard procedures, and positive or negative status was designated according to each institution's policy as recorded on the case-report form submitted to CALGB. Estrogen-receptor data were available for 99.4% of patients enrolled in the clinical trial.
Immunohistochemical Analysis for HER2 Expression
Immunohistochemical analysis with the CB11 monoclonal antibody was performed as previously described.9-11 Tissue specimens were considered to be positive for HER2 if 50% or more of breast-cancer cells stained with CB11.9-11
Immunohistochemical analysis with a polyclonal-antibody kit (Herceptest, Dako) was performed by the clinical histology laboratory of the Fletcher Allen Health Care Center according to the instructions of the manufacturer (Dako). The standard scoring method was used, and only 3+ staining was considered to be positive for HER2 overexpression.24
Fluorescence in Situ Hybridization for HER2 Amplification
Fluorescence in situ hybridization (FISH) was performed with the use of the PathVysion HER-2 DNA FISH Kit according to the instructions of the manufacturer (Vysis). For each case, 60 nonoverlapping invasive cancer nuclei were scored for the centromere enumeration probe (CEP) 17 and HER2 signals. Tissue specimens were considered to be amplified in HER2 if the HER2:CEP17 ratio was 2.00 or more.11
Statistical Analysis
The statistical analyses were specified in advance in a written correlative protocol that was approved by the Breast Cancer Intergroup of North America Correlative Science Committee and subsequently by the institutional review board of each of the laboratory investigators' institutions. The immunohistochemical assay with the CB11 monoclonal antibody and FISH for HER2 amplification constituted the principal objectives of this study; results of the polyclonal-antibody test were also evaluated. To preserve tissue and resources, a sampling scheme was developed prospectively. Two distinct and randomly selected groups of tissue samples from 750 patients were identified from the full sample of nearly 2800 available specimens. The two groups of patients were similar with respect to the number of positive lymph nodes, estrogen-receptor status, age, and treatment assignment. Results of the two principal assays in the combined groups were analyzed, whereas results of the polyclonal-antibody test were analyzed in only one group. We requested tissue specimens from 1500 women who participated in the clinical trial, and we obtained 643 and 679 tissue specimens from groups 1 and 2, respectively (a total of 1322 specimens).
The primary end point was disease-free survival, defined in the parent study as the interval from study entry until the first local or distant recurrence or death due to any cause. The interaction effect was defined as the ratio of the hazard ratios for recurrence or death with paclitaxel treatment in women with HER2-positive tumors and in those with HER2-negative tumors.
The principal analysis was based on a multivariate Cox proportional-hazards model for disease-free survival with the following covariates: paclitaxel therapy, dose of doxorubicin, square root of the number of positive nodes, tumor size, menopausal status (premenopausal vs. perimenopausal or postmenopausal), estrogen-receptor status, HER2 status, and the presence or absence of an interaction between HER2 positivity and paclitaxel. Adjustments for multiple comparisons were not performed.
Disease-free survival for the paclitaxel and no-paclitaxel groups was estimated with Kaplan–Meier curves. Third-order interactions of HER2 positivity or negativity with estrogen-receptor status and receipt or nonreceipt of paclitaxel were analyzed for hypothesis generation, and no significance levels are given for such interactions. The two methods of assessing each of the biomarkers were compared by calculating their level of agreement with the use of the kappa statistic. Results of this study are presented in accordance with reporting recommendations for tumor-marker prognostic studies (REMARK) criteria.25
Results
Outcomes and Characteristics of Selected Subgroups
The overall results of the CALGB 9344 trial with approximately 5 years of follow-up have been reported.5 With approximately 10 years of follow-up, the results have remained qualitatively similar. No significant differences in either disease-free survival or overall survival were observed for doxorubicin doses above 60 mg per square meter. The hazard ratios for recurrence and death with the use of doxorubicin doses of 60 mg per square meter as compared with 90 mg per square meter were 0.97 (95% confidence interval [CI], 0.86 to 1.13; P=0.73) and 1.03 (95% CI, 0.89 to 1.23; P=0.56), respectively. The addition of paclitaxel resulted in significant improvements in disease-free and overall survival. The hazard ratios for recurrence and death with the addition of paclitaxel after doxorubicin plus cyclophosphamide were 0.81 (95% CI, 0.73 to 0.91; P<0.001) and 0.81 (95% CI, 0.72 to 0.92; P=0.001), respectively.
To verify that each group of selected patients was representative of the entire population of women in the 9344 trial, we compared the number of involved lymph nodes, tumor size, estrogen-receptor status, and assigned treatment in the test groups and all treated patients in the trial (Table 1Table 1
Characteristics of All Treated Patients in the 9344 Trial and in This Study.). There were no detectable differences in demographic or prognostic features between groups 1 and 2 or between these groups and the remaining, unselected patients. In the combined groups, 97.4% of the patients with estrogen-receptor–positive tumors received tamoxifen, a proportion that was similar to that for the entire study (96.8%). Five-year disease-free and overall survival rates were similar for group 1 and group 2 and for the remaining, unselected patients (Table 1).Doxorubicin Dose and HER2 Status
No significant association between HER2 overexpression, according to immunohistochemical analysis with the CB11 monoclonal antibody, and escalation of the doxorubicin dose to 75 mg per square meter or 90 mg per square meter was observed in group 1 or 2 or in the combined groups. The rate of disease-free survival at 5 years in the combined groups for patients with a HER2-positive tumor who received 60 mg per square meter or for those who received 90 mg per square meter was 63% (95% CI, 52 to 76) and 63% (95% CI, 53 to 73), respectively, whereas the rate of disease-free survival at 5 years for patients with a HER2-negative tumor who received 60 mg per square meter and for those who received 90 mg per square meter was 72% (95% CI, 67 to 77) and 69% (95% CI, 64 to 74), respectively.
Paclitaxel and HER2 Status
Disease-free survival and overall survival among patients who did or did not receive paclitaxel were analyzed according to HER2 status as established by immunohistochemical analysis with the CB11 monoclonal antibody (Figure 1Figure 1
Clinical Outcomes in Patients Treated with or without Paclitaxel, According to HER2 Status.). The apparent interaction between HER2 positivity and the addition of paclitaxel in group 1 was not significant (hazard ratio for recurrence in the interaction between HER2 positivity and the addition of paclitaxel, 0.63; P=0.15) (Table 2Table 2
Results of Multivariate Models of the Interaction of HER2 Positivity and Paclitaxel Treatment.) (Figure 1A through 1D). We further examined this interaction in group 2. In group 2, the hazard ratio for recurrence in the interaction between HER2 positivity and the addition of paclitaxel was 0.52 (P=0.03) (Table 2) (Figure 1E through 1H). When the two groups were combined, in multivariate analyses the hazard ratio for recurrence in the interaction between HER2 positivity and the addition of paclitaxel to the treatment was 0.59 (P=0.01) (Table 3Table 3
Multivariate Analysis of Disease-free Survival for Groups 1 and 2 Combined.). The hazard ratio for death in the combined groups for the HER2–paclitaxel interaction was 0.57 (P=0.01) (Table 2).Paclitaxel and HER2 and Estrogen-Receptor Status
Since an estrogen-receptor–positive tumor can be a negative predictive factor for the response to chemotherapy in breast cancer,26-28 we performed an exploratory analysis of the benefit of paclitaxel based on HER2 positivity and estrogen-receptor status (Figure 2Figure 2
Disease-free Survival among Patients Treated with or without Paclitaxel According to Estrogen-Receptor Status and HER2 Expression.). For this analysis, we examined disease-free survival in the combined groups, and HER2 was evaluated with the CB11 antibody. Figure 2 shows Kaplan–Meier curves for disease-free survival in the paclitaxel and no-paclitaxel groups for each estrogen-receptor–HER2 combination. Log-rank P values are provided as a measure of discordance and should be viewed as descriptive, not inferential. In this analysis, paclitaxel was associated with improved disease-free survival among patients with HER2-positive tumors, an effect that was independent of estrogen-receptor status (Figure 2C and 2D). In the small subgroup of patients with cancers that were estrogen-receptor–positive and HER2-positive, paclitaxel appeared to be beneficial (Figure 2D). However, paclitaxel did not benefit patients with estrogen-receptor–positive, HER2-negative cancers (Figure 2B). This subgroup included more than 50% of patients in this study.Paclitaxel and Method of HER2 Analysis
We compared the results of immunohistochemical analysis with the CB11-antibody test, with the polyclonal-antibody test, and with FISH. The qualitative results of all three assays were similar (Figure 3Figure 3
Disease-free Survival among Patients Treated with or without Paclitaxel According to Different Methods of HER2 Analysis.). The interaction term between HER2 expression and a benefit from paclitaxel (within group 1 only) reached significance in only one of the three comparisons (with the polyclonal-antibody test, P=0.04; P=0.06 with FISH). The mean (±SD) kappa statistic was 85±2.6% for the level of agreement between immunohistochemical analysis with the CB11-antibody test and the polyclonal-antibody test, 79±3.2% for the level of agreement between immunohistochemical analysis with the CB11-antibody test and FISH, and 80±3.0% for the level of agreement between the polyclonal-antibody test and FISH.Discussion
We observed a significant interaction between the HER2 status of the tumor and the benefit of adjuvant paclitaxel in patients with node-positive breast cancer who received four cycles of doxorubicin plus cyclophosphamide. Our results indicate that HER2 positivity can predict improvement in disease-free survival and overall survival by the addition of paclitaxel to doxorubicin plus cyclophosphamide. In contrast, no interaction was observed between HER2 status and doses of doxorubicin above 60 mg per square meter.
The HER2–paclitaxel interaction was observed regardless of whether HER2 positivity was determined by means of either of two immunohistochemical methods or whether HER2 gene amplification was determined by means of FISH. Our data do not suggest that one assay is more robust than any other of the three. In this study, we used dichotomous cutoffs to designate whether a tumor was positive or negative for expression or amplification of HER2. A panel convened by the American Society of Clinical Oncology and the College of American Pathologists recently issued guidelines for HER2 testing by means of immunohistochemical analysis or FISH in which they proposed categories of HER2 results that should be considered to be equivocal.29,30 In our study, these categories applied to only 13 and 16 patients, respectively, precluding meaningful analyses.
In an exploratory analysis, we observed an apparent three-way interaction among HER2 positivity, estrogen-receptor negativity, and a benefit from paclitaxel. We found no benefit of paclitaxel in patients with HER2-negative, estrogen-receptor–positive breast cancer (Figure 2B). This subgroup represents more than half the patients with node-positive breast cancer who participated in the CALGB 9344 trial and who would, under most current circumstances, receive a taxane with or after cyclophosphamide plus an anthracycline. Our studies suggest that such patients could avoid the toxic effects associated with adjuvant paclitaxel when given after doxorubicin plus cyclophosphamide.5 Our results require validation before adoption into clinical practice, however.
CALGB trials that enrolled patients with node-positive breast cancer from 1985 to 1997, including the CALGB 9344 trial, showed incremental benefits in disease-free survival and overall survival.4,5,31 These studies compared what would now be considered insufficient doses of cyclophosphamide, doxorubicin, and fluorouracil with higher doses of the same regimen (CALGB 8541), the addition of paclitaxel to standard doses of doxorubicin and cyclophosphamide (CALGB 9344), and more recently, the administration of doxorubicin, cyclophosphamide, and paclitaxel every 2 weeks instead of every 3 weeks (CALGB 9741). In each case, the additional benefit of the investigational strategy as compared with the standard treatment was substantially greater in patients with estrogen-receptor–negative breast cancer than in patients with estrogen-receptor–positive breast cancer.28 However, this differential benefit was not limited to the estrogen-receptor–negative subgroup in any of these studies, suggesting that estrogen-receptor status is not an absolute predictor of a benefit from additional or dose-dense chemotherapy. The results of the present study suggest that HER2 assessment can refine predictions of a benefit from chemotherapy.
Previous studies have shown that the response to regimens containing doxorubicin at a dose of up to 60 mg per square meter is strongly correlated with HER2 amplification, overexpression, or both.9-11 Other investigators showed that any benefit from an anthracycline is associated with HER2 status and that HER2 positivity may be a surrogate for abnormalities in the topoisomerase II gene, which is present on the same amplicon as HER2.8,32 Our data, however, indicate that there is no detectable HER2–doxorubicin effect when the dose of doxorubicin is higher than 60 mg per square meter.
Preclinical data regarding HER2 status and the response to taxanes are contradictory.18,33-38 However, in one trial, patients with HER2-positive metastatic breast cancer were more likely to benefit from a paclitaxel-containing regimen than patients with HER2-negative disease19; this finding is consistent with our results.
Trastuzumab, a humanized monoclonal antibody against HER2, decreases the risks of recurrence and death among women with HER2-positive breast cancer by approximately one half and one third, respectively.39-42 We cannot speculate on how the addition of trastuzumab might affect our results. However, the benefits of trastuzumab would not affect our observation that paclitaxel appeared to have little, if any, benefit in patients with HER2-negative, estrogen-receptor–positive tumors.
We found a significant association between HER2 positivity and a benefit from the addition of paclitaxel after adjuvant treatment with doxorubicin plus cyclophosphamide in women with node-positive, stage II breast cancer. Our data raise the possibility of a three-way interaction among HER2 negativity, estrogen-receptor positivity, and a lack of benefit from paclitaxel.
Supported by grants from the National Institutes of Health (CA092461, to Dr. Hayes; and CA33601, to Dr. Berry) and from the Breast Cancer Research Foundation and the Fashion Footwear Charitable Foundation of New York/QVC Presents Shoes on Sale (to Dr. Hayes). Dako provided the Herceptest kits for HER2 immunohistochemical analysis. The research for the CALGB 9344 trial was supported in part by grants from the National Cancer Institute (CA31946, to Cancer and Leukemia Group B) and to the CALGB Statistical Center (CA33601).
The views expressed in this article are solely those of the authors and do not necessarily represent the official views of the National Cancer Institute.
Drs. Norton, Goldstein, and Berry report receiving consulting fees from Bristol-Myers Squibb; Dr. Berry, consulting fees from Abbott; and Drs. Winer and Goldstein, clinical research support from Bristol-Myers Squibb. No other potential conflict of interest relevant to this article was reported.
We thank the pathology coordinating offices of the respective participating cooperative groups (CALGB, Eastern Cooperative Oncology Group, North Central Cancer Treatment Group, and Southwest Oncology Group), and in particular Laura Monovich and Scott Jewell for their tireless efforts in cataloguing and preparing tissues for this study; Jeannette Mitchell and the immunohistochemistry laboratory of Fletcher Allen Health Care, who performed the Herceptest assays; and Dako for providing the Herceptest assay kits and special technical training.
Source Information
From the University of Michigan Comprehensive Cancer Center, Ann Arbor (D.F.H.); the University of Colorado Comprehensive Cancer Center, Aurora (A.D.T., S.E.); the Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill (L.G.D., D.C.); the University of Vermont Cancer Center, Fletcher Allen Health Care, Burlington (D.W.); Cancer and Leukemia Group B Statistical Center, Duke University, Durham, NC (G.B.); Fox Chase Comprehensive Cancer Center, Philadelphia (L.J.G.); the Angeles Clinic and Research Institute, Santa Monica, CA (S.M.); the Mayo Clinic, Rochester, MN (J.N.I.); the University of California at San Francisco, San Francisco (I.C.H.); Memorial Sloan-Kettering Cancer Center, New York (L.N., C.A.H.); the Dana–Farber Cancer Institute, Boston (E.P.W.); the Siteman Cancer Center, Washington University School of Medicine, St. Louis (M.J.E.); and the M.D. Anderson Cancer Center, Houston (D.A.B.).
Address reprint requests to Dr. Hayes at the Breast Oncology Program, 6312 Cancer Center, University of Michigan, 1500 E. Medical Center Dr., Ann Arbor, MI 48109, or at hayesdf@umich.edu.
The Cancer and Leukemia Group B (CALGB) study investigators are listed in the Appendix.
Appendix
The following investigators participated in the CALGB trial: Fox Chase Cancer Center, Philadelphia — L. Goldstein; Mayo Clinic, Rochester, MN — J.N. Ingle; CALGB Statistical Center, Duke University Medical Center, Durham, NC — S. George, J. Crawford; Dana–Farber Cancer Institute, Partners HealthCare, Boston — E.P. Winer; Dartmouth Medical School, Norris Cotton Cancer Center, Lebanon, NH — M.S. Ernstoff; Long Island Jewish Medical Center, Lake Success, NY — M. Citron; Massachusetts General Hospital, Boston — M.L. Grossbard; Medical University of South Carolina, Charleston — M. Green; Memorial Sloan-Kettering Cancer Center, New York — C. Hudis; Mount Sinai School of Medicine, New York — L.R. Silverman; North Shore University Hospital, Manhasset, NY — D.R. Budman; Rhode Island Hospital, Providence, RI — W. Sikov; Roswell Park Cancer Institute, Buffalo, NY — E. Levine; State University of New York Upstate Medical University, Syracuse — S.L. Graziano; University of Alabama at Birmingham, Birmingham — R. Diasio; University of California at San Diego, La Jolla — J. Mortimer; University of California at San Francisco, San Francisco — A.P. Venook; University of Chicago, Chicago — G. Fleming; University of Illinois, Chicago — L.E. Feldman; University of Iowa, Iowa City — G. Clamon; University of Maryland Greenebaum Cancer Center, Baltimore — M. Edelman; University of Massachusetts Medical School, Worcester — W.V. Walsh; University of Minnesota, Minneapolis — B.A Peterson; University of Missouri, Ellis Fischel Cancer Center, Columbia — M.C. Perry; University of Nebraska Medical Center, Omaha — A. Kessinger; University of North Carolina at Chapel Hill, Chapel Hill — T.C. Shea; University of Tennessee, Memphis — H.B. Niell; Vermont Cancer Center, Burlington — H.B. Muss; Wake Forest University School of Medicine, Winston-Salem, NC — D.D. Hurd; Walter Reed Army Medical Center, Washington, DC — T. Reid; Washington University School of Medicine, St. Louis — N. Bartlett; Weill Medical College of Cornell University, New York — S. Wadler.
- References
References
1
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
CrossRef | Web of Science | Medline2
Smith I ,Chua S . Medical treatment of early breast cancer. I. Adjuvant treatment. BMJ 2006;332:34-37
CrossRef | Web of Science | Medline3
Wood WC ,Budman DR ,Korzun AH , et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994;330:1253-1259[Erratum, N Engl J Med 1994;331:139.]
Full Text | Web of Science | Medline4
Budman DR ,Berry DA ,Cirrincione CT , et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst 1998;90:1205-1211
CrossRef | Web of Science | Medline5
Henderson IC ,Berry DA ,Demetri GD , et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976-983
CrossRef | Web of Science | Medline6
Slamon DJ ,Clark GM ,Wong SG ,Levin WJ ,Ullrich A ,McGuire WL . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182
CrossRef | Web of Science | Medline7
Mass RD ,Press MF ,Anderson S , et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer 2005;6:240-246
CrossRef | Medline8
Yamauchi H ,Stearns V ,Hayes DF . When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001;19:2334-2356
Web of Science | Medline9
Muss HB ,Thor AD ,Berry DA , et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330:1260-1266[Erratum, N Engl J Med 1994;331:211.]
Full Text | Web of Science | Medline10
Thor AD ,Berry DA ,Budman DR , et al. erbB2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998;90:1346-1360
CrossRef | Web of Science | Medline11
Dressler LG ,Berry DA ,Broadwater G , et al. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol 2005;23:4287-4297
CrossRef | Web of Science | Medline12
Yu D . Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers. Semin Oncol 2001;28:Suppl 16:12-17
CrossRef | Web of Science | Medline13
Formenti SC ,Spicer D ,Skinner K , et al. Low HER2/neu gene expression is associated with pathological response to concurrent paclitaxel and radiation therapy in locally advanced breast cancer. Int J Radiat Oncol Biol Phys 2002;52:397-405
CrossRef | Web of Science | Medline14
Sjostrom J ,Collan J ,von Boguslawski K , et al. C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer. Eur J Cancer 2002;38:535-542
CrossRef | Web of Science | Medline15
Tulbah AM ,Ibrahim EM ,Ezzat AA , et al. HER-2/neu overexpression does not predict response to neoadjuvant chemotherapy or prognosticate survival in patients with locally advanced breast cancer. Med Oncol 2002;19:15-23
CrossRef | Web of Science | Medline16
Van Poznak C ,Tan L ,Panageas KS , et al. Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer. J Clin Oncol 2002;20:2319-2326
CrossRef | Web of Science | Medline17
Schmidt M ,Bachhuber A ,Victor A , et al. p53 Expression and resistance against paclitaxel in patients with metastatic breast cancer. J Cancer Res Clin Oncol 2003;129:295-302
Web of Science | Medline18
Witters LM ,Santala SM ,Engle L ,Chinchilli V ,Lipton A . Decreased response to paclitaxel versus docetaxel in HER-2/neu transfected human breast cancer cells. Am J Clin Oncol 2003;26:50-54
CrossRef | Web of Science | Medline19
Konecny GE ,Thomssen C ,Luck HJ , et al. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst 2004;96:1141-1151
CrossRef | Web of Science | Medline20
Di Leo A ,Chan S ,Paesmans M , et al. HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Breast Cancer Res Treat 2004;86:197-206
CrossRef | Web of Science | Medline21
Gonzalez-Angulo AM ,Krishnamurthy S ,Yamamura Y , et al. Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinoma. Cancer 2004;101:258-263
CrossRef | Web of Science | Medline22
Rouzier R ,Perou CM ,Symmans WF , et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11:5678-5685
CrossRef | Web of Science | Medline23
Sezgin C ,Karabulut B ,Uslu R , et al. Potential predictive factors for response to weekly paclitaxel treatment in patients with metastatic breast cancer. J Chemother 2005;17:96-103
Web of Science | Medline24
Paik S ,Bryant J ,Tan-Chiu E , et al. Real-world performance of HER2 testing -- National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002;94:852-854
CrossRef | Web of Science | Medline25
McShane LM ,Altman DG ,Sauerbrei W ,Taube SE ,Gion M ,Clark GM . Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005;23:9067-9072
CrossRef | Web of Science | Medline26
Lippman ME ,Allegra JC ,Thompson EB , et al. The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med 1978;298:1223-1228
Full Text | Web of Science | Medline27
Regan MM ,Gelber RD . Predicting response to systemic treatments: learning from the past to plan for the future. Breast 2005;14:582-593
CrossRef | Web of Science | Medline28
Berry DA ,Cirrincione C ,Henderson IC , et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006;295:1658-1667[Erratum, JAMA 2006;295:2356.]
CrossRef | Web of Science | Medline29
Wolff AC ,Hammond ME ,Schwartz JN , et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145
CrossRef | Web of Science | Medline30
Wolff AC ,Hammond ME ,Schwartz JN , et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007;131:18-18
Web of Science | Medline31
Citron ML ,Berry DA ,Cirrincione C , et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431-1439[Erratum, J Clin Oncol 2003;21:2226.]
CrossRef | Web of Science | Medline32
Pritchard KI ,Shepherd LE ,O'Malley FP , et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006;354:2103-2111
Full Text | Web of Science | Medline33
Ueno NT ,Yu D ,Hung MC . Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. Oncogene 1997;15:953-960
CrossRef | Web of Science | Medline34
Pegram MD ,Lopez A ,Konecny G ,Slamon DJ . Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin Oncol 2000;27:Suppl 11:21-25
Web of Science | Medline35
Ueno NT ,Bartholomeusz C ,Herrmann JL , et al. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res 2000;6:250-259
Web of Science | Medline36
Bacus SS ,Gudkov AV ,Lowe M , et al. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene 2001;20:147-155
CrossRef | Web of Science | Medline37
Tanabe K ,Kim R ,Inoue H ,Emi M ,Uchida Y ,Toge T . Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs. Int J Oncol 2003;22:875-881
Web of Science | Medline38
Abuharbeid S ,Apel J ,Zugmaier G , et al. Inhibition of HER-2 by three independent targeting strategies increases paclitaxel resistance of SKOV-3 ovarian carcinoma cells. Naunyn Schmiedebergs Arch Pharmacol 2005;371:141-151
CrossRef | Web of Science | Medline39
Piccart-Gebhart MJ ,Procter M ,Leyland-Jones B , et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672
Full Text | Web of Science | Medline40
Romond EH ,Perez EA ,Bryant J , et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-1684
Full Text | Web of Science | Medline41
Slamon D ,Eiermann W ,Robert N , et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER-2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 2005;94:S5-S5
Web of Science42
Joensuu H ,Kellokumpu-Lehtinen P-L ,Bono P , et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-820
Full Text | Web of Science | Medline
- Citing Articles (145)
Citing Articles
1
Jennifer Glendenning, Sheeba Irshad, Andrew Tutt. (2012) Treatment of Metastatic Triple-Negative Breast Cancer. Current Breast Cancer Reports
CrossRef2
Y. Naoi, T. Tanei, K. Kishi, R. Tsunashima, N. Tominaga, Y. Baba, T. Nakayama, K. Shimazu, S.J. Kim, Y. Tamaki, S. Noguchi. (2012) 70-Gene classifier for differentiation between paclitaxel- and docetaxel-sensitive breast cancers. Cancer Letters 314:2, 206-212
CrossRef3
Helen Gogas, Urania Dafni, Maria Karina, Christos Papadimitriou, Anna Batistatou, Mattheos Bobos, Haralabos P. Kalofonos, Anastasia G. Eleftheraki, Eleni Timotheadou, Dimitrios Bafaloukos, Christos Christodoulou, Christos Markopoulos, Evangelos Briasoulis, Pavlos Papakostas, Epaminontas Samantas, Paris Kosmidis, George P. Stathopoulos, Charisios Karanikiotis, Dimitrios Pectasides, Meletios A. Dimopoulos, George Fountzilas. (2011) Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. Breast Cancer Research and Treatment
CrossRef4
L Steponaviciene, N Lachej-Mikeroviene, G Smailyte, E Aleknavicius, R Meskauskas, J Didziapetriene. (2011) Triple negative breast cancer: adjuvant chemotherapy effect on survival. Advances in Medical Sciences 56:2, 285-290
CrossRef5
Christos Vaklavas, Andres Forero-Torres. (2011) How do I Treat “Triple-Negative” Disease. Current Treatment Options in Oncology 12:4, 369-388
CrossRef6
Soley Bayraktar, Angelica M. Gutierrez-Barrera, Diane Liu, Tunc Tasbas, Ugur Akar, Jennifer K. Litton, E. Lin, Constance T. Albarracin, Funda Meric-Bernstam, Ana M. Gonzalez-Angulo, Gabriel N. Hortobagyi, Banu K. Arun. (2011) Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Research and Treatment 130:1, 145-153
CrossRef7
Michael L. Maitland, Richard L. Schilsky. (2011) Clinical trials in the era of personalized oncology. CA: A Cancer Journal for Clinicians 61:6, 365-381
CrossRef8
Xiaosong Chen, Jiayi Wu, Hongfen Lu, Ou Huang, Kunwei Shen. (2011) Measuring β-tubulin III, Bcl-2, and ERCC1 improves pathological complete remission predictive accuracy in breast cancer. Cancer Scienceno-no
CrossRef9
Mona Fiuzat, Michael R. Bristow. (2011) Pharmacogenetics in Heart Failure Trials. Heart Failure Clinics 7:4, 553-559
CrossRef10
G. Curigliano, A. Goldhirsch. (2011) The Triple-Negative Subtype: New Ideas for the Poorest Prognosis Breast Cancer. JNCI Monographs 2011:43, 108-110
CrossRef11
Kathy S. Albain. (2011) Commentary on adjuvant chemotherapy for the older woman with early stage breast cancer. The Breast 20, S150-S152
CrossRef12
Yota Yamamoto, Hiromichi Yamai, Junichi Seike, Takahiro Yoshida, Hirokazu Takechi, Yoshihito Furukita, Koichiro Kajiura, Takuya Minato, Yoshimi Bando, Akira Tangoku. (2011) Prognosis of Esophageal Squamous Cell Carcinoma in Patients Positive for Human Epidermal Growth Factor Receptor Family Can Be Improved by Initial Chemotherapy with Docetaxel, Fluorouracil, and Cisplatin. Annals of Surgical Oncology
CrossRef13
Emi Tokuda, Yuko Seino, Atsushi Arakawa, Mitsue Saito, Fujio Kasumi, Shin-ichi Hayashi, Yuri Yamaguchi. (2011) Estrogen receptor-α directly regulates sensitivity to paclitaxel in neoadjuvant chemotherapy for breast cancer. Breast Cancer Research and Treatment
CrossRef14
Shigeto Ueda, Toshiaki Saeki, Takashi Shigekawa, Jiro Omata, Tomoyuki Moriya, Junji Yamamoto, Akihiko Osaki, Nobuko Fujiuchi, Misono Misumi, Hideki Takeuchi, Takaki Sakurai, Hitoshi Tsuda, Katsumi Tamura, Jiro Ishida, Yoshiyuki Abe, Etsuko Imabayashi, Ichiei Kuji, Hiroshi Matsuda. (2011) 18F-Fluorodeoxyglucose positron emission tomography optimizes neoadjuvant chemotherapy for primary breast cancer to achieve pathological complete response. International Journal of Clinical Oncology
CrossRef15
Seung Jin Lee, Hye Young Kang, Seog Young Kim, Jin Hwa Chung, Seung Jun Oh, Jin-Sook Ryu, Sung-Bae Kim, Jong Soon Kang, Song-Kyu Park, Hwan Mook Kim, Myung-Hwa Kim, Dae Hyuk Moon. (2011) Early assessment of tumor response to JAC106, an anti-tubulin agent, by 3′-deoxy-3′-[18F]fluorothymidine in preclinical tumor models. European Journal of Nuclear Medicine and Molecular Imaging 38:8, 1436-1448
CrossRef16
Gais Kadra, Pascal Finetti, Yves Toiron, Patrice Viens, Daniel Birnbaum, Jean-Paul Borg, François Bertucci, Anthony Gonçalves. (2011) Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents. Breast Cancer Research and Treatment
CrossRef17
Jordi Ginés, Eliazar Sabater, Clara Martorell, María Grau, Marta Monroy, Miguel A. Casado. (2011) Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomised clinical trials. Clinical and Translational Oncology 13:7, 485-498
CrossRef18
Mamoru Nukatsuka, Hitoshi Saito, Fumio Nakagawa, Masaaki Abe, Junji Uchida, Jiro Shibata, Ken-ichi Matsuo, Shinzaburo Noguchi, Mamoru Kiniwa. (2011) Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts. Breast Cancer Research and Treatment 128:2, 381-390
CrossRef19
M. A. Vollebergh, E. H. Lips, P. M. Nederlof, L. F. A. Wessels, M. K. Schmidt, E. H. van Beers, S. Cornelissen, M. Holtkamp, F. E. Froklage, E. G. E. de Vries, J. G. Schrama, J. Wesseling, M. J. van de Vijver, H. van Tinteren, M. de Bruin, M. Hauptmann, S. Rodenhuis, S. C. Linn. (2011) An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Annals of Oncology 22:7, 1561-1570
CrossRef20
Marijana Rucevic, Douglas Hixson, Djuro Josic. (2011) Mammalian plasma membrane proteins as potential biomarkers and drug targets. ELECTROPHORESIS 32:13, 1549-1564
CrossRef21
Hervé Bonnefoi, Martine Piccart, Jan Bogaerts, Louis Mauriac, Pierre Fumoleau, Etienne Brain, Thierry Petit, Philippe Rouanet, Jacek Jassem, Emmanuel Blot, Khalil Zaman, Tanja Cufer, Alain Lortholary, Elisabet Lidbrink, Sylvie André, Saskia Litière, Lissandra Dal Lago, Véronique Becette, David A Cameron, Jonas Bergh, Richard Iggo. (2011) TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. The Lancet Oncology 12:6, 527-539
CrossRef22
Steve E Kalloger, Martin Köbel, Samuel Leung, Erika Mehl, Dongxia Gao, Krista M Marcon, Christine Chow, Blaise A Clarke, David G Huntsman, C Blake Gilks. (2011) Calculator for ovarian carcinoma subtype prediction. Modern Pathology 24:4, 512-521
CrossRef23
Hiroji Iwata. (2011) Neoadjuvant endocrine therapy for postmenopausal patients with hormone receptor-positive early breast cancer: a new concept. Breast Cancer 18:2, 92-97
CrossRef24
Simon Spazzapan, Diana Crivellari, Philippe Bedard, Davide Lombardi, Gianmaria Miolo, Simona Scalone, Andrea Veronesi. (2011) Therapeutic management of breast cancer in the elderly. Expert Opinion on Pharmacotherapy 12:6, 945-960
CrossRef25
Rita Nanda. (2011) “Targeting” Triple-Negative Breast Cancer: The Lessons Learned From BRCA1-Associated Breast Cancers. Seminars in Oncology 38:2, 254-262
CrossRef26
Fausto Petrelli, Sandro Barni. (2011) Meta-analysis of concomitant compared to sequential adjuvant trastuzumab in breast cancer: the sooner the better. Medical Oncology
CrossRef27
D. Zhang, E.-M. E. Hedlund, S. Lim, F. Chen, Y. Zhang, B. Sun, Y. Cao. (2011) Antiangiogenic agents significantly improve survival in tumor-bearing mice by increasing tolerance to chemotherapy-induced toxicity. Proceedings of the National Academy of Sciences 108:10, 4117-4122
CrossRef28
Natalie Galanina, Veerle Bossuyt, Lyndsay N. Harris. (2011) Molecular Predictors of Response to Therapy for Breast Cancer. The Cancer Journal 17:2, 96-103
CrossRef29
Eunjung Lee, Peter Nichols, Susan Groshen, Darcy Spicer, Amy S. Lee. (2011) GRP78 as potential predictor for breast cancer response to adjuvant taxane therapy. International Journal of Cancer 128:3, 726-731
CrossRef30
Ayca Gucalp, Tiffany A. Traina. (2011) Triple-Negative Breast Cancer: Adjuvant Therapeutic Options. Chemotherapy Research and Practice 2011, 1-13
CrossRef31
Rohit Bhargava, Nicole N. Esposito, David J. Dabbs. 2011. Immunohistology of the Breast. , 763-819.
CrossRef32
D.F. Hayes, C. Paoletti. (2011) BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Breast Diseases: A Year Book Quarterly 22:2, 160-162
CrossRef33
Ashley Davidson, Karen Gelmon. (2011) Do anthracyclines still have a role in adjuvant chemotherapy of breast cancer?. Future Oncology 7:1, 37-55
CrossRef34
Sejal Shah, Beiyun Chen. (2011) Testing for HER2 in Breast Cancer: A Continuing Evolution. Pathology Research International 2011, 1-16
CrossRef35
Jocelyne Jacquemier, Jean-Marie Boher, Henri Roche, Benjamin Esterni, Daniel Serin, Pierre Kerbrat, Fabrice Andre, Pascal Finetti, Emmanuelle Charafe-Jauffret, Anne-Laure Martin, Mario Campone, Patrice Viens, Daniel Birnbaum, Frédérique Penault-Llorca, François Bertucci. (2011) Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC - PACS 01 randomized trial. Breast Cancer Research 13:6, R109
CrossRef36
Mikiko Takikita, Ran Xie, Joon-Yong Chung, Hanbyoul Cho, Kris Ylaya, Seung-Mo Hong, Christopher A Moskaluk, Stephen M Hewitt. (2011) Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma. Journal of Translational Medicine 9:1, 126
CrossRef37
Cathy Maxwell. (2010) Biomarker Research in Breast Cancer. Clinical Journal of Oncology Nursing 14:6, 771-783
CrossRef38
S. Ressler, B. Mlineritsch, R. Greil. (2010) Triple Negative Breast Cancer. memo - Magazine of European Medical Oncology 3:4, 185-189
CrossRef39
Shaheenah Dawood. (2010) Triple-Negative Breast Cancer. Drugs 70:17, 2247-2258
CrossRef40
Foulkes, William D., Smith, Ian E., Reis-Filho, Jorge S., . (2010) Triple-Negative Breast Cancer. New England Journal of Medicine 363:20, 1938-1948
Full Text41
R. B. Costa, G. Kurra, L. Greenberg, C. E. Geyer. (2010) Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. Annals of Oncology 21:11, 2153-2160
CrossRef42
M. De Laurentiis, D. Cianniello, R. Caputo, B Stanzione, G. Arpino, S. Cinieri, V. Lorusso, S. De Placido. (2010) Treatment of triple negative breast cancer (TNBC): current options and future perspectives. Cancer Treatment Reviews 36, S80-S86
CrossRef43
Rebecca A. Burrell, Nicolai Juul, Stephen R. Johnston, Jorge S. Reis-Filho, Zoltan Szallasi, Charles Swanton. (2010) Targeting chromosomal instability and tumour heterogeneity in HER2-positive breast cancer. Journal of Cellular Biochemistry 111:4, 782-790
CrossRef44
Charles Swanton, Carlos Caldas. (2010) From genomic landscapes to personalized cancer management-is there a roadmap?. Annals of the New York Academy of Sciences 1210:1, 34-44
CrossRef45
Catherine Oakman, Giuseppe Viale, Angelo Di Leo. (2010) Management of triple negative breast cancer. The Breast 19:5, 312-321
CrossRef46
Shu-Xia Li, Ashley Sjolund, Lyndsay Harris, Joann B. Sweasy. (2010) DNA repair and personalized breast cancer therapy. Environmental and Molecular Mutagenesis 51:8-9, 897-908
CrossRef47
Y H Chia, M J Ellis, C X Ma. (2010) Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool. British Journal of Cancer 103:6, 759-764
CrossRef48
Manuel Debald, Matthias Wolfgarten, Gisela Walgenbach-Brünagel, Walther Kuhn, Michael Braun. (2010) Non-invasive proteomics—thinking about personalized breast cancer screening and treatment. The EPMA Journal 1:3, 413-420
CrossRef49
Devika Gajria, Andrew Seidman, Chau Dang. (2010) Adjuvant Taxanes: More to the Story. Clinical Breast Cancer 10:0, S41-S49
CrossRef50
Fabrice Andre, Zineb Benbrahim, Suzette Delaloge. (2010) Breast Cancer Classification to Select Patients for Cancer Treatment. Current Breast Cancer Reports 2:3, 152-158
CrossRef51
Richard Simon. (2010) Moving from correlative science to predictive oncology. The EPMA Journal 1:3, 377-387
CrossRef52
Sally Greenberg, Hope S. Rugo. (2010) Challenging Clinical Scenarios: Treatment of Patients With Triple-Negative or Basal-Like Metastatic Breast Cancer. Clinical Breast Cancer 10:0, S20-S29
CrossRef53
Miguel Martín, Álvaro Rodríguez-Lescure, Amparo Ruiz, Emilio Alba, Lourdes Calvo, Manuel Ruiz-Borrego, Ana Santaballa, César A. Rodríguez, Carmen Crespo, Mar Abad, Severina Domínguez, Jesús Florián, Cristina Llorca, Miguel Méndez, María Godes, Ricardo Cubedo, Adolfo Murias, Norberto Batista, María José García, Rosalía Caballero, Enrique Álava. (2010) Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment 123:1, 149-157
CrossRef54
I. Craig Henderson. (2010) Adjuvant chemotherapy is not for everyone. Breast Cancer Research and Treatment 123:1, 159-162
CrossRef55
Yutaka Yamamoto, Hirotaka Iwase. (2010) Clinicopathological features and treatment strategy for triple-negative breast cancer. International Journal of Clinical Oncology 15:4, 341-351
CrossRef56
M Tanioka, C Shimizu, K Yonemori, K Yoshimura, K Tamura, T Kouno, M Ando, N Katsumata, H Tsuda, T Kinoshita, Y Fujiwara. (2010) Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy. British Journal of Cancer 103:3, 297-302
CrossRef57
Catherine M. Kelly, Gabriel N. Hortobagyi. (2010) Adjuvant Chemotherapy in Early-Stage Breast Cancer: What, When, and for Whom?. Surgical Oncology Clinics of North America 19:3, 649-668
CrossRef58
Michael S. Sabel. (2010) Sentinel Lymph Node Biopsy Before or After Neoadjuvant Chemotherapy: Pros and Cons. Surgical Oncology Clinics of North America 19:3, 519-538
CrossRef59
Melinda L. Telli, James M. Ford. (2010) Novel Treatment Approaches for Triple-Negative Breast Cancer. Clinical Breast Cancer 10:0, E16-E22
CrossRef60
Harry D. Bear. (2010) Neoadjuvant Chemotherapy for Operable Breast Cancer: Individualizing Locoregional and Systemic Therapy. Surgical Oncology Clinics of North America 19:3, 607-626
CrossRef61
Ellis, Matthew, . (2010) Taxane-Based Chemotherapy for Node-Positive Breast Cancer — Take-Home Lessons. New England Journal of Medicine 362:22, 2122-2124
Full Text62
Zeina Nahleh. (2010) Neoadjuvant chemotherapy for “Triple Negative” breast cancer: a review of current practice and future outlook. Medical Oncology 27:2, 531-539
CrossRef63
M R Baneshi, P Warner, N Anderson, J Edwards, T G Cooke, J M S Bartlett. (2010) Tamoxifen resistance in early breast cancer: statistical modelling of tissue markers to improve risk prediction. British Journal of Cancer 102:10, 1503-1510
CrossRef64
Richard L. Schilsky. (2010) Personalized medicine in oncology: the future is now. Nature Reviews Drug Discovery 9:5, 363-366
CrossRef65
Y. Y. Shao, K. T. Kuo, F. C. Hu, Y. S. Lu, C. S. Huang, J. Y. Liau, W. C. Lee, C. Hsu, W. H. Kuo, K. J. Chang, C. H. Lin, A. L. Cheng. (2010) Predictive and Prognostic Values of Tau and ERCC1 in Advanced Breast Cancer Patients Treated with Paclitaxel and Cisplatin. Japanese Journal of Clinical Oncology 40:4, 286-293
CrossRef66
Maki Tanaka, Yasushi Takamatsu, Keisei Anan, Shinji Ohno, Reiki Nishimura, Yutaka Yamamoto, Norikazu Masuda, Shoshu Mitsuyama, Kazuo Tamura. (2010) Oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: a phase II study. Anti-Cancer Drugs 21:4, 453-458
CrossRef67
Emad A. Rakha, Jorge S. Reis-Filho, Ian O. Ellis. (2010) Combinatorial biomarker expression in breast cancer. Breast Cancer Research and Treatment 120:2, 293-308
CrossRef68
Malini Harigopal, William E. Barlow, Greg Tedeschi, Peggy L. Porter, I-Tien Yeh, Charles Haskell, Robert Livingston, Gabriel N. Hortobagyi, George Sledge, Charles Shapiro, James N. Ingle, David L. Rimm, Daniel F. Hayes. (2010) Multiplexed Assessment of the Southwest Oncology Group-Directed Intergroup Breast Cancer Trial S9313 by AQUA Shows that Both High and Low Levels of HER2 Are Associated with Poor Outcome. The American Journal of Pathology 176:4, 1639-1647
CrossRef69
Ignasi Tusquets, Laura García-Estévez, Encarna Adrover, Lourdes Calvo, Isabel Álvarez, Jesús García Mata, Yolanda Fernández, Mireia Margueli, Miquel Ángel Seguí, César Rodríguez, Álvaro Rodríguez Lescure, Ramon Colomer, Pere Gascón, Miguel Martín, Emilio Alba, Agusti Barnadas, Antonio Llombart, Joan Albanell, Ana Lluch. (2010) Current controversies in the management of breast cancer. Clinical and Translational Oncology 12:4, 278-286
CrossRef70
Omer Dizdar, Kadri Altundag. (2010) Current and emerging treatment options in triple-negative breast cancer. Oncology Reviews 4:1, 5-13
CrossRef71
Yasuo Ohashi, Toru Watanabe, Muneaki Sano, Hiroki Koyama, Hideo Inaji, Takaichiro Suzuki. (2010) Efficacy of oral tegafur-uracil (UFT) as adjuvant therapy as compared with classical cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in early breast cancer: a pooled analysis of two randomized controlled trials (N·SAS-BC 01 trial and CUBC trial). Breast Cancer Research and Treatment 119:3, 633-641
CrossRef72
Ramachandran Venkitaraman. (2010) Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features. Expert Review of Anticancer Therapy 10:2, 199-207
CrossRef73
Mandira Ray, Blase N. Polite. (2010) Triple-Negative Breast Cancers. The Cancer Journal 16:1, 17-22
CrossRef74
Steven J. Isakoff. (2010) Triple-Negative Breast Cancer. The Cancer Journal 16:1, 53-61
CrossRef75
Richard Simon. (2010) Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology. Personalized Medicine 7:1, 33-47
CrossRef76
Kathy S Albain, William E Barlow, Steven Shak, Gabriel N Hortobagyi, Robert B Livingston, I-Tien Yeh, Peter Ravdin, Roberto Bugarini, Frederick L Baehner, Nancy E Davidson, George W Sledge, Eric P Winer, Clifford Hudis, James N Ingle, Edith A Perez, Kathleen I Pritchard, Lois Shepherd, Julie R Gralow, Carl Yoshizawa, D Craig Allred, C Kent Osborne, Daniel F Hayes. (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. The Lancet Oncology 11:1, 55-65
CrossRef77
Martin Köbel, Steve E. Kalloger, Jennifer L. Santos, David G. Huntsman, C. Blake Gilks, Kenneth D. Swenerton. (2010) Tumor type and substage predict survival in stage I and II ovarian carcinoma: Insights and implications. Gynecologic Oncology 116:1, 50-56
CrossRef78
Philippe L. Bedard, Angelo Di Leo, Martine J. Piccart-Gebhart. (2010) Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. Nature Reviews Clinical Oncology 7:1, 22-36
CrossRef79
Anna Bergamaschi, Geir Olav Hjortland, Tiziana Triulzi, Therese Sørlie, Hilde Johnsen, Anne Hansen Ree, Hege Giercksky Russnes, Sigurd Tronnes, Gunhild M. Mælandsmo, Oystein Fodstad, Anne-Lise Borresen-Dale, Olav Engebraaten. (2009) Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models. Molecular Oncology 3:5-6, 469-482
CrossRef80
Miguel Martin, Parham Khosravi. (2009) Retrospective subset analyses in early breast cancer revisited. The Lancet Oncology 10:12, 1136-1137
CrossRef81
O. Gluz, C. Liedtke, N. Gottschalk, L. Pusztai, U. Nitz, N. Harbeck. (2009) Triple-negative breast cancer--current status and future directions. Annals of Oncology 20:12, 1913-1927
CrossRef82
V. Pullarkat, M. L. Slovak, A. Dagis, V. Bedell, G. Somlo, R. Nakamura, A. S. Stein, M. R. O'Donnell, A. Nademanee, A. L. Teotico, S. Bhatia, S. J. Forman. (2009) Acute leukemia and myelodysplasia after adjuvant chemotherapy for breast cancer: durable remissions after hematopoietic stem cell transplantation. Annals of Oncology 20:12, 2000-2006
CrossRef83
Carey K. Anders, Lisa A. Carey. (2009) Biology, Metastatic Patterns, and Treatment of Patients With Triple-Negative Breast Cancer. Clinical Cancer Reviews 3:1, 39-47
CrossRef84
Richard Simon. (2009) Advances in clinical trial designs for predictive biomarker discovery and validation. Current Breast Cancer Reports 1:4, 216-221
CrossRef85
R. M. Simon, S. Paik, D. F. Hayes. (2009) Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers. JNCI Journal of the National Cancer Institute 101:21, 1446-1452
CrossRef86
Timothy Quill, Tristin Abair, Kristin Garcia. (2009) The American Society of Clinical Oncology 2009 Breast Cancer Symposium. Clinical Breast Cancer 9:4, 213-218
CrossRef87
A. Schneeweiss. (2009) Mammakarzinom. Der Gynäkologe 42:11, 841-846
CrossRef88
Nan Soon Wong, Benjamin O Anderson, Kei Siong Khoo, Peng Tiam Ang, Cheng Har Yip, Yen-Shen Lu, Narind Voravud, Zhi-Ming Shao, Kathleen I Pritchard. (2009) Management of HER2-positive breast cancer in Asia: consensus statement from the Asian Oncology Summit 2009. The Lancet Oncology 10:11, 1077-1085
CrossRef89
Carol A. Parise, Katrina R. Bauer, Monica M. Brown, Vincent Caggiano. (2009) Breast Cancer Subtypes as Defined by the Estrogen Receptor (ER), Progesterone Receptor (PR), and the Human Epidermal Growth Factor Receptor 2 (HER2) among Women with Invasive Breast Cancer in California, 1999-2004. The Breast Journal 15:6, 593-602
CrossRef90
Yuka Sasaki, Hitoshi Tsuda. (2009) Clinicopathological characteristics of triple-negative breast cancers. Breast Cancer 16:4, 254-259
CrossRef91
T.H. Oude Munnink, W.B. Nagengast, A.H. Brouwers, C.P. Schröder, G.A. Hospers, M.N. Lub-de Hooge, E. van der Wall, P.J. van Diest, E.G.E. de Vries. (2009) Molecular imaging of breast cancer. The Breast 18, S66-S73
CrossRef92
Richard D. Gelber, Shari Gelber. (2009) Facilitating consensus by examining patterns of treatment effects. The Breast 18, S2-S8
CrossRef93
Sabine C. Linn, Laura J. Van 't Veer. (2009) Clinical relevance of the triple-negative breast cancer concept: Genetic basis and clinical utility of the concept. European Journal of Cancer 45, 11-26
CrossRef94
Irfan Cicin, Hakan Karagol, Ufuk Usta, Atakan Sezer, Sernaz Uzunoglu, Rusen Alas-Cosar, Tarkan Yetisyigit, Kazim Uygun. (2009) Triple negative breast cancer compared to hormone receptor negative/HER2 positive breast cancer. Medical Oncology 26:3, 335-343
CrossRef95
Donald A Berry. (2009) Adjuvant chemotherapy for breast cancer in older women. Women's Health 5:5, 453-457
CrossRef96
Mona Fiuzat, G Michael Felker, Mark P Donahue, Christopher M O’Connor. (2009) Using genetic information to select treatment for patients with heart failure: has the time come?. Personalized Medicine 6:4, 385-392
CrossRef97
Xiang H.-F. Zhang, Qiongqing Wang, William Gerald, Clifford A. Hudis, Larry Norton, Marcel Smid, John A. Foekens, Joan Massagué. (2009) Latent Bone Metastasis in Breast Cancer Tied to Src-Dependent Survival Signals. Cancer Cell 16:1, 67-78
CrossRef98
H. Masmoudi, S.M. Hewitt, N. Petrick, K.J. Myers, M.A. Gavrielides. (2009) Automated Quantitative Assessment of HER-2/neu Immunohistochemical Expression in Breast Cancer. IEEE Transactions on Medical Imaging 28:6, 916-925
CrossRef99
2009. Early Symptomatic Breast Cancer. , 1-67.
CrossRef100
Chad A. Livasy. (2009) Triple-Negative Breast Carcinoma. Surgical Pathology Clinics 2:2, 247-261
CrossRef101
Paul Ellis, Peter Barrett-Lee, Lindsay Johnson, David Cameron, Andrew Wardley, Susan O'Reilly, Mark Verrill, Ian Smith, John Yarnold, Robert Coleman, Helena Earl, Peter Canney, Chris Twelves, Christopher Poole, David Bloomfield, Penelope Hopwood, Stephen Johnston, Mitchell Dowsett, John MS Bartlett, Ian Ellis, Clare Peckitt, Emma Hall, Judith M Bliss. (2009) Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. The Lancet 373:9676, 1681-1692
CrossRef102
Danielle M. Nevarez, Yemane A. Mengistu, Irosha N. Nawarathne, Kevin D. Walker. (2009) An N -Aroyltransferase of the BAHD Superfamily Has Broad Aroyl CoA Specificity in Vitro with Analogues of N -Dearoylpaclitaxel. Journal of the American Chemical Society 131:16, 5994-6002
CrossRef103
Ursula B McGovern, Justin Stebbing. (2009) Receptor-based predictors of response in breast cancer. Future Oncology 5:3, 283-286
CrossRef104
Heather-Jane Au, Kamran Golmohammadi, Tallal Younis, Shailendra Verma, Stephen Chia, Konrad Fassbender, Philip Jacobs. (2009) Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects. Breast Cancer Research and Treatment 114:3, 579-587
CrossRef105
John Mackey, Deanna McLeod, Joseph Ragaz, Karen Gelmon, Sunil Verma, Kathleen Pritchard, Kara Laing, Louise Provencher, Lauren F. Charbonneau. (2009) Adjuvant targeted therapy in early breast cancer. Cancer 115:6, 1154-1168
CrossRef106
Tsing-Fen Ho, Yu-Ta Peng, Show-Mei Chuang, Shin-Chang Lin, Bo-Lin Feng, Chien-Hsing Lu, Wan-Ju Yu, Jo-Shu Chang, Chia-Che Chang. (2009) Prodigiosin down-regulates survivin to facilitate paclitaxel sensitization in human breast carcinoma cell lines. Toxicology and Applied Pharmacology 235:2, 253-260
CrossRef107
Dana Faratian, Ashley Graham, Frances Rae, Jeremy Thomas. (2009) Rapid screening of tissue microarrays for Her-2 fluorescence in situ hybridization testing is an accurate, efficient and economic method of providing an entirely in situ hybridization-based Her-2 testing service. Histopathology 54:4, 428-432
CrossRef108
Jeruss, Jacqueline S., Woodruff, Teresa K., . (2009) Preservation of Fertility in Patients with Cancer. New England Journal of Medicine 360:9, 902-911
Full Text109
Tadahiko Shien, Sadako Akashi-Tanaka, Kunihisa Miyakawa, Takashi Hojo, Chikako Shimizu, Kunihiko Seki, Masashi Ando, Tsutomu Kohno, Naruto Taira, Hiroyoshi Doihara, Noriyuki Katsumata, Yasuhiro Fujiwara, Takayuki Kinoshita. (2009) Clinicopathological Features of Tumors as Predictors of the Efficacy of Primary Neoadjuvant Chemotherapy for Operable Breast Cancer. World Journal of Surgery 33:1, 44-51
CrossRef110
A.D. Seidman, C.G. Murphy. (2009) Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer. Breast Diseases: A Year Book Quarterly 19:4, 353-355
CrossRef111
A K Koutras, K T Kalogeras, M-A Dimopoulos, R M Wirtz, U Dafni, E Briasoulis, D Pectasides, H Gogas, C Christodoulou, G Aravantinos, G Zografos, E Timotheadou, P Papakostas, H Linardou, E Razis, T Economopoulos, H P Kalofonos, G Fountzilas. (2008) Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: A Hellenic Cooperative Oncology Group (HeCOG) study. British Journal of Cancer 99:11, 1775-1785
CrossRef112
Juan Bayo, María Lomas, Javier Salvador, Alberto Moreno, Manuel Ruiz, Alberto Rodríguez, José Fuentes, Ana Fernández-Freire, Reyes Bernabé, Andrea Fernández. (2008) A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer. Clinical and Translational Oncology 10:12, 817-825
CrossRef113
Nilufer Bulut, Sadettin Kilickap, Ebru Sari, Kadri Altundag. (2008) Response to taxanes in triple negative breast cancer. Cancer Chemotherapy and Pharmacology 63:1, 189-189
CrossRef114
Yeon Hee Park, Hae Hyun Jung, Jin Seok Ahn, Young-Hyuck Im. (2008) Ets-1 upregulates HER2-induced MMP-1 expression in breast cancer cells. Biochemical and Biophysical Research Communications 377:2, 389-394
CrossRef115
H. B. Muss. (2008) Adjuvant chemotherapy for older women with breast cancer. Breast Cancer Online 11:11,
CrossRef116
Antoinette R. Tan, Sandra M. Swain. (2008) Therapeutic Strategies for Triple-Negative Breast Cancer. The Cancer Journal 14:6, 343-351
CrossRef117
Gert Stockmans, Karen Deraedt, Hans Wildiers, Philippe Moerman, Robert Paridaens. (2008) Triple-negative breast cancer. Current Opinion in Oncology 20:6, 614-620
CrossRef118
Federico Rojo, Joan Albanell, Ana Rovira, Josep Maria Corominas, Felix Manzarbeitia. (2008) Targeted therapies in breast cancer. Seminars in Diagnostic Pathology 25:4, 245-261
CrossRef119
Mark R. Green, Stephen L. George, Richard L. Schilsky. (2008) Tomorrow's Cancer Treatments Today: The First 50 Years of the Cancer and Leukemia Group B. Seminars in Oncology 35:5, 470-483
CrossRef120
Linda Vahdat. (2008) Choosing a taxane for adjuvant treatment of breast cancer: more than a flip of the coin?. Nature Clinical Practice Oncology 5:10, 570-571
CrossRef121
Maurie Markman. (2008) The remarkable “paclitaxel story”: How many chapters remain to be written?. Gynecologic Oncology 111:1, 7-8
CrossRef122
Bruce J. Giantonio, Arlene A. Forastiere, Robert L. Comis. (2008) The Role of the Eastern Cooperative Oncology Group in Establishing Standards of Cancer Care: Over 50 Years of Progress Through Clinical Research. Seminars in Oncology 35:5, 494-506
CrossRef123
Yaacov Richard Lawrence, Maria Werner-Wasik, Adam P Dicker. (2008) Biologically conformal treatment: biomarkers and functional imaging in radiation oncology. Future Oncology 4:5, 689-704
CrossRef124
Kai-Keen Shiu, David SP Tan, Jorge S Reis-Filho. (2008) Development of therapeutic approaches to ‘triple negative’ phenotype breast cancer. Expert Opinion on Therapeutic Targets 12:9, 1123-1137
CrossRef125
Neesha Dhani, Lillian L. Siu. (2008) Clinical trials and biomarker development with molecularly targeted agents and radiotherapy. Cancer and Metastasis Reviews 27:3, 339-349
CrossRef126
M Spears, J Kenicer, A F Munro, JMS Bartlett. (2008) Type I receptor tyrosine kinases as predictive or prognostic markers in early breast cancer. Biomarkers in Medicine 2:4, 397-407
CrossRef127
Federica Cuppone, Emilio Bria, Paolo Carlini, Michele Milella, Alessandra Felici, Isabella Sperduti, Cecilia Nisticò, Edmondo Terzoli, Francesco Cognetti, Diana Giannarelli. (2008) Taxanes as primary chemotherapy for early breast cancer. Cancer 113:2, 238-246
CrossRef128
C. Hudis, C. Dang. (2008) The Taxane Limbo: How Low Can We Go?. JNCI Journal of the National Cancer Institute 100:11, 761-763
CrossRef129
M. Martin, A. Rodriguez-Lescure, A. Ruiz, E. Alba, L. Calvo, M. Ruiz-Borrego, B. Munarriz, C. A. Rodriguez, C. Crespo, E. de Alava, J. A. Lopez Garcia-Asenjo, M. D. Guitian, S. Almenar, J. F. Gonzalez-Palacios, F. Vera, J. Palacios, M. Ramos, J. M. Gracia Marco, A. Lluch, I. Alvarez, M. A. Segui, J. I. Mayordomo, A. Anton, J. M. Baena, A. Plazaola, A. Modolell, A. Pelegri, J. R. Mel, E. Aranda, E. Adrover, J. V. Alvarez, J. L. Garcia Puche, P. Sanchez-Rovira, S. Gonzalez, J. M. Lopez-Vega, . (2008) Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer. JNCI Journal of the National Cancer Institute 100:11, 805-814
CrossRef130
D A Berry. (2008) The screening mammography paradox: better when found, perhaps better not to find. British Journal of Cancer 98:11, 1729-1730
CrossRef131
Richard L Schilsky. (2008) How not to treat cancer. The Lancet Oncology 9:6, 504-505
CrossRef132
Richard Simon. (2008) Designs and adaptive analysis plans for pivotal clinical trials of therapeutics and companion diagnostics. Expert Opinion on Medical Diagnostics 2:6, 721-729
CrossRef133
Sudeep Gupta. (2008) HER2 positivity predicts a benefit from paclitaxel treatment after adjuvant chemotherapy. Nature Clinical Practice Oncology 5:5, 252-253
CrossRef134
Gerald M Higa, Jame Abraham. (2008) Ixabepilone: a new microtubule-targeting agent for breast cancer. Expert Review of Anticancer Therapy 8:5, 671-681
CrossRef135
Mr J Michael Dixon. (2008) Role of ErbB2 in selection for adjuvant tamoxifen or aromatase inhibitors. Women's Health 4:3, 229-231
CrossRef136
Sparano, Joseph A., Wang, Molin, Martino, Silvana, Jones, Vicky, Perez, Edith A., Saphner, Tom, Wolff, Antonio C., Sledge, George W. Jr., Wood, William C., Davidson, Nancy E., . (2008) Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer. New England Journal of Medicine 358:16, 1663-1671
Full Text137
Hitoshi Tsuda. (2008) Individualization of breast cancer based on histopathological features and molecular alterations. Breast Cancer 15:2, 121-132
CrossRef138
Lionel Apetoh, Grégoire Mignot, Theocharis Panaretakis, Guido Kroemer, Laurence Zitvogel. (2008) Immunogenicity of anthracyclines: moving towards more personalized medicine. Trends in Molecular Medicine 14:4, 141-151
CrossRef139
M. J. Ellis. (2008) Improving Outcomes for Patients With Hormone Receptor-Positive Breast Cancer: Back to the Drawing Board. JNCI Journal of the National Cancer Institute 100:3, 159-161
CrossRef140
M. Anderssona, A. Awadab, P. Barrett-Leec, P. Ellisd, P. Hupperetse, C. Jackischf, E. Kubistag, H.-J. Lückh, C. Monnerati, U. Nitzj, M. Untchl. (2008) European oncologists' preferences for the management of breast cancer: case presentations and expert commentary. The Breast 17, S1-S12
CrossRef141
(2008) HER2 and Response to Paclitaxel in Node-Positive Breast Cancer. New England Journal of Medicine 358:2, 197-199
Full Text142
S. Paik, Y. Taniyama, C. E. Geyer. (2008) Anthracyclines in the Treatment of HER2-Negative Breast Cancer. JNCI Journal of the National Cancer Institute 100:1, 2-4
CrossRef143
Birgitte B Rasmussen, Meredith M Regan, Anne E Lykkesfeldt, Patrizia Dell'Orto, Barbara Del Curto, Katrine L Henriksen, Mauro G Mastropasqua, Karen N Price, Eliane Méry, Magali Lacroix-Triki, Stephen Braye, Hans J Altermatt, Richard D Gelber, Monica Castiglione-Gertsch, Aron Goldhirsch, Barry A Gusterson, Beat Thürlimann, Alan S Coates, Giuseppe Viale. (2008) Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. The Lancet Oncology 9:1, 23-28
CrossRef144
Jin Zhang, Yan Liu. (2008) HER2 over-expression and response to different chemotherapy regimens in breast cancer. Journal of Zhejiang University SCIENCE B 9:1, 5-9
CrossRef145
Moore, Anne, . (2007) Breast-Cancer Therapy — Looking Back to the Future. New England Journal of Medicine 357:15, 1547-1549
Full Text
- Letters
